Healx

Healx is a British pharmaceutical company that describes itself as the first AI-native rare disease pharma. Founded in 2014 by Dr Tim Guilliams and Dr David Brown, the company was inspired by Nick Sireau, a patient advocate who spent a decade searching for treatments for an extremely rare genetic disorder affecting his sons. Tim and Dave had long advocated drug redevelopment—using existing drugs for new therapeutic purposes—combined with artificial intelligence, and they recognized that this inexpensive and accelerated approach could help the rare disease community find treatments faster. Healx focuses on rare diseases, a category of over 10,000 conditions affecting 300 million people worldwide, 90% of which have no approved treatment. Traditional drug discovery is slow, expensive, and has a 5% success rate, which has led to a culture of filling pipelines with blockbuster drugs targeted to large patient populations. Healx aims to change this by using AI and other frontier technologies to redevelop, combine, and enhance known compounds, building a pipeline of new and effective therapies. The company states that AI enables it to rapidly identify which novel drug-disease relationships have the highest chance of success and to scale a drug pipeline that delivers significant patient impact. By using technology to de-risk the drug discovery process, Healx can run multiple programmes in parallel and deliver a higher chance of treatment success. Healx brings treatments from prediction to patient. Its pipeline includes HLX-4310, which is being evaluated in a Phase 1/2 trial for metastatic recurrence and progression in sarcomas, with a focus on osteosarcoma. The company also partners with patient groups and other organizations to progress treatments for rare diseases. Healx is headquartered in Cambridge, United Kingdom, and operates globally. It is a private company, described as a startup in Wikidata.

Healx was founded in 2014 by Dr Tim Guilliams and Dr David Brown. The idea for the company emerged when they met Nick Sireau, a man who had set up a patient group to find treatments for an extremely rare genetic disorder that affected his sons. For a decade, Nick worked tirelessly, but the drug discovery process was slow and very expensive—a challenge facing nearly all patient groups. Tim and Dave had long been advocating drug redevelopment—the use of existing drugs for new therapeutic purposes—when used in combination with artificial intelligence. They knew that this inexpensive and accelerated approach could help others like Nick and the rare disease community overcome the challenges they were facing and find treatments faster. Nick became their inspiration—he was the living story of the therapeutic need their approach could meet. Since its founding, Healx has positioned itself as the first AI-native rare disease pharma. The company has built a pipeline of new and effective therapies by using AI and other frontier technologies to redevelop, combine, and enhance known compounds. Healx states that AI enables it to rapidly identify which novel drug-disease relationships have the highest chance of success and to scale a drug pipeline that will deliver significant patient impact. By using technology to de-risk the drug discovery process, Healx can run multiple programmes in parallel and deliver a higher chance of treatment success. A key milestone in Healx's history is the advancement of HLX-4310 into a Phase 1/2 trial. The company announced the first patient dosed in this trial to evaluate the effect of HLX-4310 on metastatic recurrence and progression in sarcomas, with a focus on osteosarcoma. Healx continues to partner with patient groups and other organizations to progress treatments for rare diseases. The company is headquartered in Cambridge, United Kingdom, and operates globally.

• 2014

  Healx founded by Dr Tim Guilliams and Dr David Brown.

• Healx announces first patient dosed in Phase 1/2 trial of HLX-4310 for sarcomas, focusing on osteosarcoma.

AI-native rare disease pharma using artificial intelligence to redevelop, combine, and enhance known compounds for rare diseases.

• HLX-4310

  An investigational therapy in Phase 1/2 trial for metastatic recurrence and progression in sarcomas, with a focus on osteosarcoma.

• 2019.10.16

  Reported2019.10.16

  Healx announces $56 million Series B financing[4]Healx宣布完成5600万美元B轮融资finanznachrichten.de

  Healx announced that it had raised $56 million in a Series B financing round led by Atomico, with Intel Capital, Global Brain and btov Partners joining, and previous investors also participating.

Read more

1. 1Healx | AI drug discovery | Rare disease treatmenthealx.ai
2. 2About - Healxhealx.ai
3. 3healx - Wikidatawikidata.org
4. 4Healx宣布完成5600万美元B轮融资finanznachrichten.de